Structural and functional neuroimaging in Alzheimer's disease
The evolution of neuroimaging technics has improved our understanding of both gross structural and physiological alterations associated with normal aging and with Alzheimer's disease. We share the optimistic view that neuroimaging will contribute to the development of antemortem markers for AD. Current CT and MRI technics allow for direct parenchymal sampling in addition to quantitating CSF distributions. Such studies followed to postmortem will yield the evidence regarding the diagnostic utility of the imaged parenchymal changes. Metabolic neuroimaging using PET and tracers for glycolytic metabolism have already contributed to our understanding of the pathophysiology of AD and its relationship to clinical symptoms. We can look forward to further advances with specific tracers for brain receptor populations and other metabolic pathways. © 1986.
Digital Object Identifier (DOI)
Additional Document Info